Clinicopathologic Analysis of Early-stage Sporadic Ovarian Carcinoma

American Journal of Surgical Pathology

Volumn 28, Issue 2, 2004, Pages 147-159

  Leitao Jr , Mario M ^a   Boyd, Jeff ^a   Hummer, Amanda ^a   Olvera, Narciso ^a   Arroyo, Crispinita D ^a   Venkatraman, Ennapadam ^a   Baergen, Rebecca N ^a   Dizon, Don S ^b   Barakat, Richard R ^a   Soslow, Robert A ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Borderline tumors; Early stage invasive ovarian cancer; Prognostic variables; Sporadic ovarian cancer; TP53 gene mutation

Indexed keywords

BRCA PROTEIN; EOSIN; GENE PRODUCT; HEMATOXYLIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; BREAST CARCINOMA; BRENNER TUMOR; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIOID CARCINOMA; FAMILY HISTORY; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; MIXED TUMOR; MUCINOUS CARCINOMA; OVARY CARCINOMA; PREOPERATIVE PERIOD; PROGNOSIS; REVIEW;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS;

EID: 9144253147     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200402000-00001     Document Type: Review

References (71)

1. Ahmed FY, Wiltshaw E, A'hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol. 1996;14:2968-2975.
2. Baak JP, Langley FA, Talerman A, et al. Interpathologist and intrapathologist disagreement in ovarian tumor grading and typing. Anal Quant Cytol Histol. 1986;8:354-357.
3. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255-258.
4. Bell DA, Scully RE. Benign and borderline clear cell adenofibromas of the ovary. Cancer. 1985;56:2922-2931.
5. Bell DA, Weinstock MA, Scully RE. Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis. Cancer. 1988;62:2212-2222.
6. Bell KA, Kurman RJ. A clinicopathologic analysis of atypical proliferative (borderline) tumors and well-differentiated endometrioid adenocarcinomas of the ovary. Am J Surg Pathol. 2000;24:1465-1479.
7. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. Am J Surg Pathol. 2001;25:419-432.
8. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol. 2002;20:463-466.
9. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol. 1995;6:887-893.
10. Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol. 1997;64:196-206.
11. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
12. Casey G, Lopez ME, Ramos JC, et al. DNA sequence analysis of exons 2 through II and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 1996;13:1971-1981.
13. Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001;80:56-61.
14. Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm Trial I: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. International Collaborative Ovarian Neoplasm (ICONI) Collaborators. J Natl Cancer Inst. 2003;95:125-132.
15. Deavers MT, Gershenson DM, Tortolero-Luna G, et al. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases. Am J Surg Pathol. 2002;26:1129-1141.
16. Dembo AJ, Davy M, Stenwig AE, et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol. 1990;75:263-272.
17. Eichhorn JH, Bell DA, Young RH, et al. Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns. Am J Surg Pathol. 1999;23:397-409.
18. Eltabbakh GH, Belinson JL, Kennedy AW, et al. p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer. Cancer. 1997;80:892-898.
19. Geisler JP, Geisler HE, Miller GA, et al. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol. 2000;77:278-282.
20. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risks. Ann Statistics. 1988;16:1141-1154.
21. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol. 1994;12:64-69.
22. Heintz APM, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6:107-138.
23. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
24. Kendall BS, Ronnett BM, Isacson C, et al. Reproducibility of the diagnosis of endometrial hyperplasia, atypical hyperplasia, and well-differentiated carcinoma. Am J Surg Pathol. 1998;22:1012-1019.
25. Kohler MF, Kerns BM, Humphrey PA, et al. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 1993;81:643-650.
26. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002;85:351-355.
27. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of II cases with 'pseudomyxoma peritonei.' Am J Surg Pathol. 2000;24:1447-1464.
28. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-292.
29. Leitao M, Soslow R, Olvera N, et al. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol Oncol. (in press).
30. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456.
31. Longacre TA, Chung MH, Jensen DN, et al. Proposed criteria for the diagnosis of well-differentiated endometrial carcinoma: a diagnostic test for myoinvasion. Am J Surg Pathol. 1995;19:371-406.
32. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991;51:2979-2984.
33. Monga M, Carmichael JA. Shelley W, et al. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol. 1991;43:195-197.
34. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001;32:368-378.
35. Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance. Br J Cancer. 1994;70:1191-1197.
36. Ovarian Cancer. Screening, Treatment, and Followup. NIH Consensus Statement Online. 1994; April 5-7;[cited Oct 28, 2002] 12 3:1-30.
37. rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000:981-1057.
38. Petru E, Lahousen M, Tamussino K, et al. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170:656-662.
39. Pirog EC, Baergen RN, Soslow RA, et al. Diagnostic accuracy of cervical low-grade squamous intraepithelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol. 2002;26:70-75.
40. Prat J, de Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. Am J Surg Pathol. 2002;26:1111-1128.
41. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617-635.
42. Ronnett BM, Kurman RJ, Shmookler BM, et al. The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites. Am J Surg Pathol. 1997;21:1144-1155.
43. Rosai J. Borderline epithelial lesions of the breast. Am J Surg Pathol. 1991;15:209-221.
44. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med. 1996;335:1413-1416.
45. Rubin SC, Wong GYC, Curtin JP, et al. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol. 1993;82:143-147.
46. Schildkraut JM, Halabi S, Bastos E, et al. Prognostic factors in early-onset epithelial ovarian cancer: a population-based study. Obstet Gynecol. 2000;95:119-127.
47. Schnitt SJ, Connolly JL, Tavassoli FA, et al. Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria. Am J Surg Pathol. 1992;16:1133-1143.
48. Scully RE. World Health Organization. International Histological Classification of Tumours: Histological Typing of Ovarian Tumours. Heidelberg: Springer, 1999.
49. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol. 2000;31:539-557.
50. Seidman JD, Kurman RJ. Subclassification of serous borderline tumors of the ovary into benign and malignant types: a clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol. 1996;20:1331-1345.
51. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
52. Sevelda P, Dittrich C, Salzer H. Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol Oncol. 1989;35:321-322.
53. Sevelda P, Vavra N, Schemper M, et al. Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer. 1990;65:2349-2352.
54. Shahin MS, Hughes JH, Sood AK, et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer. 2000;89:2006-2017.
55. Skomedal H, Kristensen GB, Abeler VM, et al. TP53 protein accumulation and gene mutation in relation to overexpression of mdm2 protein in ovarian borderline tumours and stage I carcinomas. J Pathol. 1997;181:158-165.
56. Slomovitz BM, Caputo TA, Gretz HF, et al. A comparative analysis of 57 serous borderline tumors with and without a noninvasive micropapillary component. Am J Surg Pathol. 2002;26:592-600.
57. Soussi T, Dehouche K, Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat. 2000;15:105-113.
58. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
59. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm Trial I and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112.
60. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J Natl Cancer Inst. 2003;95:113-125.
61. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
62. Vergote IB, Kaern J, Abeler VM, et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am J Obstet Gynecol. 1993;169:40-52.
63. Weir MM, Bell DA, Young RH. Grade I peritoneal serous carcinomas: a report of 14 cases and comparison with 7 peritoneal serous psammocarcinomas and 19 peritoneal serous borderline tumors. Am J Surg Pathol. 1998;22:849-862.
64. Wen WH, Reles A, Runnebaum IB, et al. p53 mutations and expression in ovarian cancers: correlation with overall survival. Int J Gynecol Pathol. 1999;18:29-41.
65. Winter WE, Kucera PR, Rodgers W, et al. Surgical staging in patients with ovarian tumors of low malignant potential. Obstet Gynecol. 2002;100:671-676.
66. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.
67. Young RC, Pecorelli S. Management of early ovarian cancer. Semin Oncol. 1998;25:335-339.
68. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990;322:1021-1027.
69. Young RC. Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol. 2000;27(suppl 7):8-10.
70. Zanetta G, Rota S, Chiari S, et al. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 2001;19:2658-2664.
71. Zanetta G, Rota S, Chiari S, et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma: a multivariate analysis. Ann Oncol. 1998;9:1097-1101.